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Between Scylla and Charybdis 
The ethical dilemmas of treating fulminant (or subful-
minant) hepatic failure with liver replacement have been 
apparent since the earliest trials of this procedure. Acute 
hepatic failure was the indication for orthotopic liver 
transplantation in only I of our first 237 recipients I and 
accounted for only 8 of the next 300.2 Our reluctance to 
proceed with more cases was that unlike candidates 
whose livers are chronically diseased, those with acute or 
subacute hepatic failure may spontaneously recover. The 
vast majority of patients who pass through the acute cri-
sis are able to regenerate their own livers and return to 
a normal life expectancy, absent the burden of chronic 
immunosuppression. The incidence of a favorable out-
come is strongly influenced by the cause of the hepatic 
failure, highest with hepatitis A (67%) and acetamino-
phen overdose (53%). The lowest recovery is with non-
A. non-B, and non-C hepatitis and after poisoning with 
halothane or other hepatotoxic drugs. 
No matter what the etiology, the prognosis for recov-
ery. short ofliver transplantation, currently is better than 
the 5% to 10% frequently cited from the literature of the 
I 970s. which discussed the option of conservative man-
agement. The improvement requires specialized care 
teams armed with protocols designed to prevent brain 
injury. Hopital Paul Brousse. from which the report by 
Bismuth et al. 3 comes, has such services. However. sur-
vival is not as good as that after liver transplantation. 
at least within the context of the 1- to 5-year follow-up. 
Consequently. liver surgeons currently are recapitulating 
the era preceding 1962 in kidney transplantation. when 
artificial kidney support was not available widely-if at 
all-for the treatment of acute renal failure. Then with 
the kidney. as currently with the liver. the first objective 
Was to differentiate those patients who would recover 
from those who were doomed without draconian inter-
Vention. 
In a further analogy to the history of acute renal tubu-
lar necrosis and kidney transplantation. the inherent re-
versibility of fulminant hepatic failure has driven re-
search that eventuallv mav reduce the need for liver 
transplantation. thil~ the' body's hepatic based meta-
bolic machinery grinds to a halt, all of the organ systems 
are threatened. but the most dreaded insult is to the cen-
tral nervous system. The minimal extra function pro-
vided by extra- or intracorporeal hepatic allografts or xe-
nografts, and more recently by hepatocytes injected in-
travenously or lining the capillary tubes of "artificial 
livers," has been credited with amelioration of brain de-
terioration and other complications of liver failure (in-
cluding renal dysfunction). Buying limited time in this 
way with a borrowed animal or human liver (or hepato-
cytes) could be a hollow gesture, but since 1975, a family 
of hepatic growth factors has been discovered which may 
speed the regeneration of the devastated native liver.4 
These molecules have not yet been successfully exploited 
clinically, partially because of the inability to maintain 
life support long enough for their effect to be evaluated. 
The key to success appears to be artificial liver support 
combined with iatrogenic promotion of hepatic regener-
ation. 
When these technologies are developed. emergency 
liver transplantation for fulminant hepatic failure will 
become largely obsolete. Until then and even afterward. 
the choice of aggressive medical versus transplant ther-
apy will remain. With either decision. the best results al-
ways will be with the patients who are the least ill, the 
ones who historically have been the most likely to re-
cover with no specific treatment at all. Unfortunately. in 
such cases. a highly visible and professionally damaging 
error will lie in wait for the physician or surgeon who 
delays operation until a patient who might have been 
saved by transplantation has lost that chance. In con-
trast. the invisible error of operating on patients who 
would have recovered spontaneously is seldom discussed 
and rarely is provable. The frequency of the latter mis-
take and its lifetime implications for the recipient is cer-
tain to increase the earlier the timing of transplantation 
is decided. 
The experience of Bismuth et al. 3 was acquired in this 
treacherous landscape. between Scylla and Charybdis. 
Of the 139 patients entered into their study. 23 were 
withdrawn-22 by death after a mean of 1.3 days and the 
other by spontaneous recovery. The 23 candidates who 
did not make it to the operating room cannot be con-
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strued as a nonsurgical control series with a survival of 
4.4% because the time to death was shorter than the av· 
erage time required to obtain an organ. Apparently, most 
of these patients were not viable with either an operative 
or nonoperative strategy. 
The overall I-year survival of the 116 patients who 
came to transplantation was 68%. However, it was 83% 
for those with precoma (n = 6) or grade I and 2 coma (n 
= 47) compared with 55.6% for those who had reached 
grade 3 coma (n = 63). It was refreshing to see the French 
authors wade through the arcate terminology of hepatic 
failure stages (I-IV) and coma grades (1-4) with simpli-
fied information. Those who could still fend off abuse 
constituted the cohort with 83% survival, and those who 
could not protect themselves made up the 55.6% survival 
group. In another clarifying statistic. they noted that 
81.1 % of patients who survived could breath unaided 
preoperatively versus 63.2% when ventilator support was 
needed. The simplicity also should be noted of the so-
called Benhamou classification of disease severity-de-
pending essentially on the two determinants of coma 
grade and level of coagulation factor V -compared with 
more complex schemes used in many other European 
centers and in the United States. 
Our own experience over the last decade, in which ful-
minant and subfulminant hepatic failure accounted for 
<3% of the total case load, has been similar to that of 
the Paris team. 5 However, for the reasons discussed by 
Bismuth et al.,3 we do not use ABO incompatible, stea-
totic, or otherwise marginal livers for these very ill pa-
tients. The survival and avoidance of retransplantation 
hinges more on achieving good function promptly than 
on promptly receiving a graft that would not be accept-
able for the average candidate with end-stage chronic dis-
ease. 
The article by Bismuth et al. 3 is an important one in 
the narrow context of acute and subacute hepatic failure. 
~-AM. Surg.· August t99S 
More importantly, it exposes the philosophy of this su-
perb team about the place ofliver transplantation in the 
armamentarium against liver disease. The guiding prin-
ciple of the French group was the prompt transplanta-
tion for, not avoidance of. those candidates thought most 
certain to die without such intervention. No sophistic ar-
guments were advanced in this or their preceding publi-
cations that the life survival curve could be improved by 
relegating the "statistically dangerous" patients to non-
candidacy. The day-to-day, hands-on practice of such 
professional rectitude is beyond the reach of teams pos-
sessing less skill and depth. However, an equally respon-
sible solution for relatively inexperienced teams is 
prompt referral of very ill patients to specialty centers. 
rather than the pronouncement of these cases as hopeless 
when they merely are grave. If the conventional process 
of triage with tertiary care referral is applicable to pa-
tients with acute hepatic failure, it is difficult to compre-
hend the recommendation of a vociferous minority of 
liver transplant surgeons that profoundly ill patients with 
chronic liver disease should be bypassed in favor of treat-
ing less disabled elective candidates. 
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